First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Express Scripts to add Zepbound to National Preferred Formulary
This acquisition marks Max Healthcare's entry into Lucknow
There has been no loss or injury to human life
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
The company is assessing the situation and simultaneously undertaking all the requisite action
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
